BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 10364381)

  • 1. Common neutralization epitope in minor capsid protein L2 of human papillomavirus types 16 and 6.
    Kawana K; Yoshikawa H; Taketani Y; Yoshiike K; Kanda T
    J Virol; 1999 Jul; 73(7):6188-90. PubMed ID: 10364381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region.
    Kondo K; Ishii Y; Ochi H; Matsumoto T; Yoshikawa H; Kanda T
    Virology; 2007 Feb; 358(2):266-72. PubMed ID: 17010405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nasal immunization of mice with peptide having a cross-neutralization epitope on minor capsid protein L2 of human papillomavirus type 16 elicit systemic and mucosal antibodies.
    Kawana K; Kawana Y; Yoshikawa H; Taketani Y; Yoshiike K; Kanda T
    Vaccine; 2001 Jan; 19(11-12):1496-502. PubMed ID: 11163673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A surface immunodeterminant of human papillomavirus type 16 minor capsid protein L2.
    Kawana K; Matsumoto K; Yoshikawa H; Taketani Y; Kawana T; Yoshiike K; Kanda T
    Virology; 1998 Jun; 245(2):353-9. PubMed ID: 9636375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal antibodies recognizing cross-neutralization epitopes in human papillomavirus 16 minor capsid protein L2.
    Nakao S; Mori S; Kondo K; Matsumoto K; Yoshikawa H; Kanda T
    Virology; 2012 Dec; 434(1):110-7. PubMed ID: 23051711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human papillomavirus type 16 minor capsid protein l2 N-terminal region containing a common neutralization epitope binds to the cell surface and enters the cytoplasm.
    Kawana Y; Kawana K; Yoshikawa H; Taketani Y; Yoshiike K; Kanda T
    J Virol; 2001 Mar; 75(5):2331-6. PubMed ID: 11160736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minor Capsid Protein L2 Polytope Induces Broad Protection against Oncogenic and Mucosal Human Papillomaviruses.
    Pouyanfard S; Spagnoli G; Bulli L; Balz K; Yang F; Odenwald C; Seitz H; Mariz FC; Bolchi A; Ottonello S; Müller M
    J Virol; 2018 Feb; 92(4):. PubMed ID: 29212932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A protective and broadly cross-neutralizing epitope of human papillomavirus L2.
    Gambhira R; Karanam B; Jagu S; Roberts JN; Buck CB; Bossis I; Alphs H; Culp T; Christensen ND; Roden RB
    J Virol; 2007 Dec; 81(24):13927-31. PubMed ID: 17928339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The N-terminal region of the human papillomavirus L2 protein contains overlapping binding sites for neutralizing, cross-neutralizing and non-neutralizing antibodies.
    Rubio I; Seitz H; Canali E; Sehr P; Bolchi A; Tommasino M; Ottonello S; Müller M
    Virology; 2011 Jan; 409(2):348-59. PubMed ID: 21074234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimeric human papillomavirus type 16 (HPV-16) L1 particles presenting the common neutralizing epitope for the L2 minor capsid protein of HPV-6 and HPV-16.
    Varsani A; Williamson AL; de Villiers D; Becker I; Christensen ND; Rybicki EP
    J Virol; 2003 Aug; 77(15):8386-93. PubMed ID: 12857908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent anti-HPV immune responses induced by tandem repeats of the HPV16 L2 (20 -- 38) peptide displayed on bacterial thioredoxin.
    Rubio I; Bolchi A; Moretto N; Canali E; Gissmann L; Tommasino M; Müller M; Ottonello S
    Vaccine; 2009 Mar; 27(13):1949-56. PubMed ID: 19368776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural variants in the major neutralizing epitope of human papillomavirus minor capsid protein L2.
    Seitz H; Schmitt M; Böhmer G; Kopp-Schneider A; Müller M
    Int J Cancer; 2013 Feb; 132(3):E139-48. PubMed ID: 22961598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Type specific and genotype cross reactive B epitopes of the L1 protein of HPV16 defined by a panel of monoclonal antibodies.
    Kulski JK; Sadleir JW; Kelsall SR; Cicchini MS; Shellam G; Peng SW; Qi YM; Galloway DA; Zhou J; Frazer IH
    Virology; 1998 Apr; 243(2):275-82. PubMed ID: 9568027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
    Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
    J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17-36 epitopes.
    Jagu S; Karanam B; Wang JW; Zayed H; Weghofer M; Brendle SA; Balogh KK; Tossi KP; Roden RBS; Christensen ND
    Vaccine; 2015 Oct; 33(42):5553-5563. PubMed ID: 26382603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A three component mix of thioredoxin-L2 antigens elicits broadly neutralizing responses against oncogenic human papillomaviruses.
    Seitz H; Canali E; Ribeiro-Müller L; Pàlfi A; Bolchi A; Tommasino M; Ottonello S; Müller M
    Vaccine; 2014 May; 32(22):2610-7. PubMed ID: 24662712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses.
    Combita AL; Touzé A; Bousarghin L; Christensen ND; Coursaget P
    J Virol; 2002 Jul; 76(13):6480-6. PubMed ID: 12050360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric L2-Based Virus-Like Particle (VLP) Vaccines Targeting Cutaneous Human Papillomaviruses (HPV).
    Huber B; Schellenbacher C; Shafti-Keramat S; Jindra C; Christensen N; Kirnbauer R
    PLoS One; 2017; 12(1):e0169533. PubMed ID: 28056100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conformational and linear epitopes on virus-like particles of human papillomavirus type 33 identified by monoclonal antibodies to the minor capsid protein L2.
    Volpers C; Sapp M; Snijders PJ; Walboomers JM; Streeck RE
    J Gen Virol; 1995 Nov; 76 ( Pt 11)():2661-7. PubMed ID: 7595373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2.
    Alphs HH; Gambhira R; Karanam B; Roberts JN; Jagu S; Schiller JT; Zeng W; Jackson DC; Roden RB
    Proc Natl Acad Sci U S A; 2008 Apr; 105(15):5850-5. PubMed ID: 18413606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.